583 related articles for article (PubMed ID: 33208340)
21. Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.
van Ramshorst MS; van Werkhoven E; Honkoop AH; Dezentjé VO; Oving IM; Mandjes IA; Kemper I; Smorenburg CH; Stouthard JM; Linn SC; Sonke GS;
Breast; 2016 Oct; 29():153-9. PubMed ID: 27498129
[TBL] [Abstract][Full Text] [Related]
22. Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial.
van der Voort A; van Ramshorst MS; van Werkhoven ED; Mandjes IA; Kemper I; Vulink AJ; Oving IM; Honkoop AH; Tick LW; van de Wouw AJ; Mandigers CM; van Warmerdam LJ; Wesseling J; Vrancken Peeters MT; Linn SC; Sonke GS
JAMA Oncol; 2021 Jul; 7(7):978-984. PubMed ID: 34014249
[TBL] [Abstract][Full Text] [Related]
23. Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial.
Blohmer JU; Link T; Reinisch M; Just M; Untch M; Stötzer O; Fasching PA; Schneeweiss A; Wimberger P; Seiler S; Huober J; Thill M; Jackisch C; Rhiem K; Solbach C; Hanusch C; Seither F; Denkert C; Engels K; Nekljudova V; Loibl S;
JAMA Oncol; 2022 Jul; 8(7):1010-1018. PubMed ID: 35588050
[TBL] [Abstract][Full Text] [Related]
24. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
[TBL] [Abstract][Full Text] [Related]
25. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).
Sikov WM; Berry DA; Perou CM; Singh B; Cirrincione CT; Tolaney SM; Kuzma CS; Pluard TJ; Somlo G; Port ER; Golshan M; Bellon JR; Collyar D; Hahn OM; Carey LA; Hudis CA; Winer EP
J Clin Oncol; 2015 Jan; 33(1):13-21. PubMed ID: 25092775
[TBL] [Abstract][Full Text] [Related]
26. Neoadjuvant carboplatin in triple-negative breast cancer: results from NACATRINE, a randomized phase II clinical trial.
de Pádua Souza C; Carneiro ASB; de Oliveira Lessa AC; Lacerda DC; Paiva CE; Zorzetto MMC; de Freitas AJA; Santana IVV; de Oliveira MA; Palmero EI; Marques MMC; Reinert T
Breast Cancer Res Treat; 2023 Nov; 202(1):57-65. PubMed ID: 37578666
[TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
van Ramshorst MS; van der Voort A; van Werkhoven ED; Mandjes IA; Kemper I; Dezentjé VO; Oving IM; Honkoop AH; Tick LW; van de Wouw AJ; Mandigers CM; van Warmerdam LJ; Wesseling J; Vrancken Peeters MT; Linn SC; Sonke GS;
Lancet Oncol; 2018 Dec; 19(12):1630-1640. PubMed ID: 30413379
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis of feasibility and rates of pathologic complete response.
Kern P; Kalisch A; Kolberg HC; Kimmig R; Otterbach F; von Minckwitz G; Sikov WM; Pott D; Kurbacher C
Chemotherapy; 2013; 59(5):387-94. PubMed ID: 24852315
[TBL] [Abstract][Full Text] [Related]
29. The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer.
Abraham JE; Pinilla K; Dayimu A; Grybowicz L; Demiris N; Harvey C; Drewett LM; Lucey R; Fulton A; Roberts AN; Worley JR; Chhabra A; Qian W; Vallier AL; Hardy RM; Chan S; Hickish T; Tripathi D; Venkitaraman R; Persic M; Aslam S; Glassman D; Raj S; Borley A; Braybrooke JP; Sutherland S; Staples E; Scott LC; Davies M; Palmer CA; Moody M; Churn MJ; Newby JC; Mukesh MB; Chakrabarti A; Roylance RR; Schouten PC; Levitt NC; McAdam K; Armstrong AC; Copson ER; McMurtry E; Tischkowitz M; Provenzano E; Earl HM
Nature; 2024 May; 629(8014):1142-1148. PubMed ID: 38588696
[TBL] [Abstract][Full Text] [Related]
30. FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer.
Oliveira M; Saura C; Nuciforo P; Calvo I; Andersen J; Passos-Coelho JL; Gil Gil M; Bermejo B; Patt DA; Ciruelos E; de la Peña L; Xu N; Wongchenko M; Shi Z; Singel SM; Isakoff SJ
Ann Oncol; 2019 Aug; 30(8):1289-1297. PubMed ID: 31147675
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of weekly paclitaxel plus carboplatin followed by anthracycline chemotherapy on the neoadjuvant treatment of patients with triple-negative breast cancer.
Castrellon AB; Velez M; Nguyen SM; Blaya M; Barnick S; Dumais K; LeCroy N; Raez LE
Hematol Oncol Stem Cell Ther; 2018 Mar; 11(1):30-33. PubMed ID: 29100977
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
Mittendorf EA; Zhang H; Barrios CH; Saji S; Jung KH; Hegg R; Koehler A; Sohn J; Iwata H; Telli ML; Ferrario C; Punie K; Penault-Llorca F; Patel S; Duc AN; Liste-Hermoso M; Maiya V; Molinero L; Chui SY; Harbeck N
Lancet; 2020 Oct; 396(10257):1090-1100. PubMed ID: 32966830
[TBL] [Abstract][Full Text] [Related]
34. A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer.
Yam C; Mittendorf EA; Garber HR; Sun R; Damodaran S; Murthy RK; Ramirez D; Karuturi M; Layman RM; Ibrahim N; Rauch GM; Adrada BE; Candelaria RP; White JB; Ravenberg E; Clayborn A; Ding QQ; Symmans WF; Prabhakaran S; Thompson AM; Valero V; Tripathy D; Huo L; Moulder SL; Litton JK
Breast Cancer Res Treat; 2023 Jun; 199(3):457-469. PubMed ID: 37061619
[TBL] [Abstract][Full Text] [Related]
35. CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer.
Shepherd JH; Ballman K; Polley MC; Campbell JD; Fan C; Selitsky S; Fernandez-Martinez A; Parker JS; Hoadley KA; Hu Z; Li Y; Soloway MG; Spears PA; Singh B; Tolaney SM; Somlo G; Port ER; Ma C; Kuzma C; Mamounas E; Golshan M; Bellon JR; Collyar D; Hahn OM; Hudis CA; Winer EP; Partridge A; Hyslop T; Carey LA; Perou CM; Sikov WM
J Clin Oncol; 2022 Apr; 40(12):1323-1334. PubMed ID: 35044810
[TBL] [Abstract][Full Text] [Related]
36. Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy.
Luen SJ; Salgado R; Dieci MV; Vingiani A; Curigliano G; Gould RE; Castaneda C; D'Alfonso T; Sanchez J; Cheng E; Andreopoulou E; Castillo M; Adams S; Demaria S; Symmans WF; Michiels S; Loi S
Ann Oncol; 2019 Feb; 30(2):236-242. PubMed ID: 30590484
[TBL] [Abstract][Full Text] [Related]
37. Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis.
Cortes J; Haiderali A; Huang M; Pan W; Schmid P; Akers KG; Park JE; Frederickson AM; Fasching PA; O'Shaughnessy J
BMC Cancer; 2023 Aug; 23(1):792. PubMed ID: 37612624
[TBL] [Abstract][Full Text] [Related]
38. Pembrolizumab for Early Triple-Negative Breast Cancer.
Schmid P; Cortes J; Pusztai L; McArthur H; Kümmel S; Bergh J; Denkert C; Park YH; Hui R; Harbeck N; Takahashi M; Foukakis T; Fasching PA; Cardoso F; Untch M; Jia L; Karantza V; Zhao J; Aktan G; Dent R; O'Shaughnessy J;
N Engl J Med; 2020 Feb; 382(9):810-821. PubMed ID: 32101663
[TBL] [Abstract][Full Text] [Related]
39. Both carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysis.
Chen XS; Yuan Y; Garfield DH; Wu JY; Huang O; Shen KW
PLoS One; 2014; 9(9):e108405. PubMed ID: 25247558
[TBL] [Abstract][Full Text] [Related]
40. De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial.
Gluz O; Nitz U; Kolberg-Liedtke C; Prat A; Christgen M; Kuemmel S; Mohammadian MP; Gebauer D; Kates R; Paré L; Grischke EM; Forstbauer H; Braun M; Warm M; Hackmann J; Uleer C; Aktas B; Schumacher C; Wuerstlein R; Graeser M; Pelz E; Jóźwiak K; Zu Eulenburg C; Kreipe HH; Harbeck N;
Clin Cancer Res; 2022 Nov; 28(22):4995-5003. PubMed ID: 35797219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
